Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Ono Pharmaceutical Co., Ltd. (OTCMKTS: OPHLY) today announced an ...

CHICAGO -- Mifepristone (Korlym) reduced HbA1c levels in patients with inadequately controlled type 2 diabetes and ...

US biopharma Vertex Pharmaceuticals and Japanese drugmaker Ono Pharmaceutical have announced an exclusive collaboration and ...

US drugmaker Vertex Pharmaceuticals has announced simultaneous presentation and publication of updated data from the Phase ...

Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; "Ono") and Vertex Pharmaceuticals Incorporated (Headquarters: Boston, MA, U.S.; CEO: Reshma Kewalramani, M.D ...

Vertex Pharmaceuticals has shared data from the Phase I/II segment of the Phase I/II/III FORWARD-101 trial, evaluating ...

Vertex Pharmaceuticals may have narrowed its focus this year, but the biopharma’s decision to stick with its remaining islet ...

While BMO Capital Markets said that zimislecel is “highly encouraging” for type 1 diabetes, questions regarding its target ...

"This edition of the Healthcare Enforcement column discusses two judicial decisions from recent months relating to the ...

In phase 2 of the FORWARD study, 83% of participants with type 1 diabetes achieved insulin independence a year after receiving zimislecel (formerly VX-880), an islet cell therapy developed ...

With this reimbursement, approximately 45 people with cystic fibrosis in Australia will become eligible for a CFTR modulator for the first time –– ...

Vertex Pharmaceuticals locked arms with Ono Pharmaceutical in an exclusive deal to advance povetacicept, targeting B ...